[1]李志坤,魏丹蕾,杨树月,等.柴胡桂枝干姜汤对2型糖尿病大鼠肠道菌群及短链脂肪酸的影响研究[J].陕西中医,2024,(6):757-762.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.007]
　LI Zhikun,WEI Danlei,YANG Shuyue,et al.Effects of Chaihu Guizhi Ganjiang decoction on gut microbiota and short-chain fatty acids in type 2 diabetes rats[J].,2024,(6):757-762.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.007]
点击复制

柴胡桂枝干姜汤对2型糖尿病大鼠肠道菌群及短链脂肪酸的影响研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年6期
页码:
757-762
栏目:
基础研究
出版日期:
2024-06-05

文章信息/Info

Title:
Effects of Chaihu Guizhi Ganjiang decoction on gut microbiota and short-chain fatty acids in type 2 diabetes rats
作者:
李志坤; 魏丹蕾; 杨树月; 陈丽兰; 胡丽竹; 李宝玲; 林春挺
(广州医科大学附属中医医院,广东 广州 510130)
Author(s):
LI Zhikun; WEI Danlei; YANG Shuyue; CHEN Lilan; HU Lizhu; LI Baoling; LIN Chunting
(The Affiliated TCM Hospital of Guangzhou Medical University,Guangzhou 510130,China)
关键词:
2型糖尿病;  柴胡桂枝干姜汤;  肠道菌群;  乳酸杆菌属;  短链脂肪酸;  丁酸
Keywords:
Type 2 diabetes;  Chaihu Guizhi Ganjiang decoction;  Gut microbiota;  Lactobacillus;  Short-chain fatty acids;  Butyrate
分类号:
R 255.4
DOI:
DOI:10.3969/j.issn.1000-7369.2024.06.007
文献标志码:
A
摘要:
目的:探讨柴胡桂枝干姜汤对2型糖尿病(T2DM)大鼠肠道菌群及短链脂肪酸的影响。方法:将Wistar大鼠随机分为正常组、模型组和柴胡桂枝干姜汤组。正常组8只,予正常饲料喂养,其余22只予高脂高糖饲料喂养6周后,腹腔注射链脲佐菌素(STZ)32 mg/kg进行T2DM造模,最后共有18只大鼠造模成功,将18只T2DM大鼠随机分为模型组和柴胡桂枝干姜汤组,每组9只。正常组和模型组予0.9%氯化钠溶液10 ml/kg进行灌胃,柴胡桂枝干姜汤组予柴胡桂枝干姜汤11.24 g/kg灌胃,每天给药2次,持续给药8周。使用罗氏血糖仪检测空腹血糖(FBG); ELISA法检测糖化血红蛋白(HbA1c); 利用Novaseq 6000系统对肠道微生物16S rDNA的V3 + V4区进行扩增测序; 利用液相色谱-质谱检测粪便短链脂肪酸水平。 结果:与正常组比较,模型组的FBG及干预8周后的HbA1c显著升高(P<0.05),干预前后的HbA1c差值显著增大(P<0.05),厚壁菌门、乳酸杆菌属的相对丰度显著下降(P<0.05),拟杆菌门、瘤胃球菌属的相对丰度显著增加(P<0.05),丁酸和异丁酸含量显著上调(P<0.05),而主要产丁酸菌如毛螺杆菌科、普雷沃氏菌科、双歧杆菌科和粪杆菌属的相对丰度无明显增加,差异无统计学意义(P>0.05),拟杆菌科的相对丰度出现下降(P<0.05)。与模型组比较,柴胡桂枝干姜汤组在干预6周后的FBG显著下降(P<0.05),干预前后的HbA1c差值显著减少(P<0.05),厚壁菌门、乳酸杆菌属的相对丰度显著增加(P<0.05),瘤胃球菌属的相对丰度显著下降(P<0.05),丁酸含量显著下降(P<0.05),毛螺杆菌科、普雷沃氏菌科、双歧杆菌科和拟杆菌科的相对丰度差异无统计学意义(P>0.05),粪杆菌属相对丰度显著上升(P<0.05)。结论:柴胡桂枝干姜汤能够改善2型糖尿病大鼠的FBG及HbA1c,其作用可能与增加乳酸杆菌属丰度、减少瘤胃球菌属丰度以及调节短链脂肪酸的代谢吸收有关。
Abstract:
Objective:To investigate the effects of Chaihu Guizhi Ganjiang decoction on gut microbiota and short-chain fatty acids in type 2 diabetes(T2DM)rats.Methods:Wistar rats were randomly divided into a normal group,a model group,and a Chaihu Guizhi Ganjiang decoction group.A normal group of 8 rats were fed with normal feed,while the remaining 22 rats were fed with high-fat and high sugar feed for 6 weeks.After intraperitoneal injection of Streptozotocin(STZ)at a dose of 32 mg/kg,T2DM models were established.Finally,a total of 18 rats were successfully established.The 18 T2DM rats were randomly divided into a model group and a Chaihu Guizhi Ganjiang decoction group,with 9 rats in each group.The normal group and model group were given 10 ml/kg of physiological saline by gavage,while the Chaihu Guizhi Ganjiang decoction group was given 11.24 g/kg of Chaihu Guizhi Ganjiang decoction by gavage twice a day for 8 weeks.Use a Roche blood glucose meter to measure fasting blood glucose(FBG); ELISA method for detecting glycated hemoglobin A1c(HbA1c); the Novaseq 6000 system to sequence the V3+V4 region of 16S rDNA from gut microbiota; liquid chromatography-mass spectrometry(LC-MS)to detect fecal short chain fatty acid levels.Results:Compared with the normal group,the FBG and HbA1c of the model group were significantly increased(P<0.05)after 8 weeks of intervention,and the difference in HbA1c before and after intervention was significantly increased(P<0.05).The relative abundance of Firmicutes and Lactobacillus genera were significantly decreased(P<0.05),while the relative abundance of Bacteroidetes and Ruminococcus genera were significantly increased(P<0.05).The content of butyric acid and isobutyric acid was significantly upregulated(P<0.05),while the main butyric acid producing bacteria such as Lachnospiraceae,Prevotellaceae,Bifidobacteriaceae,and Faecalibaculum did not show a significant increase,with no statistically significant difference(P>0.05),and even the relative abundance of Bacteroideaceae decreased(P<0.05).Compared with the model group,the Chaihu Guizhi Ganjiang decoction group showed a significant decrease in FBG after 6 weeks of intervention(P<0.05),a significant decrease in HbA1c difference before and after intervention(P<0.05),a significant increase in relative abundance of Firmicutes and Lactobacillus genera(P<0.05),a significant decrease in relative abundance of Ruminococcus genus(P<0.05),and a significant decrease in butyric acid content(P<0.05),while the main butyric acid producing bacteria such as Lachnospiraceae,Prevotellaceae,Bifidobacteriaceae and Bacteroideaceae did not significantly decrease,and the difference was not statistically significant(P>0.05),and the relative abundance of Faecalibaculum significantly increased(P<0.05).Conclusion:Chaihu Guizhi Ganjiang decoction can improve FBG and HbA1c in type 2 diabetes rats,which may be related to increasing the abundance of Lactobacillus,reducing the abundance of Ruminococcus and regulating the metabolism and absorption of short chain fatty acids.

参考文献/References:

[1] 马晓军.外周血C肽、糖化血红蛋白和血糖水平与2型糖尿病患者并发症发生关系及其预测价值研究[J].陕西医学杂志,2023,52(9):1211-1213.
[2] 杨雀,陈伟国,高海燕,等.德谷门冬双胰岛素和甘精胰岛素治疗预混胰岛素血糖控制不佳2型糖尿病疗效及安全性研究[J].陕西医学杂志,2023,52(1):86-88.
[3] 李婷,苏虹霞,段玉红,等.中医辨证联合辅助干预治疗2型糖尿病疗效研究[J].陕西中医,2022,43(12):1725-1728.
[4] 巩祥贺,何平鸽,王鑫,等.从“四位一体”与“郁热虚损”角度探讨柴胡桂枝干姜汤在2型糖尿病中的应用[J].环球中医药,2023,16(9):1833-1836.
[5] 刘晶.柴胡桂枝干姜汤化裁治疗寒热错杂型糖尿病的临床观察[J].中国民间疗法,2022,30(23):87-90.
[6] 周鹏,孙妲男,李勇,等.解毒活血汤对慢性肾脏病大鼠肾脏FGF23、Klotho表达的影响[J].陕西中医,2024,45(1):13-16.
[7] 王天君,刘晓鹰.柴胡桂枝干姜汤病机浅析[J].环球中医药,2022,15(9):1652-1655.
[8] 张慈安,刘煊,岳小强.柴胡桂枝干姜汤在消化系统疾病中应用举隅[J].浙江中医杂志,2023,58(9):695-696.
[9] 赵会忠.柴胡桂枝干姜汤对2型糖尿病患者血糖、血脂影响的临床研究[J].糖尿病新世界,2023,26(19):76-79.
[10] CUNNINGHAM A L,STEPHENS J W,HARRIS D A.A review on gut microbiota:A central factor in the pathophysiology of obesity[J].Lipids Health Dis,2021,20(1):65-66.
[11] ZHANG L,CHU J,HAO W,et al.Gut microbiota and type 2 diabetes mellitus:Association,mechanism,and translational applications[J].Mediators Inflamm,2021,2021(10):1155-1167.
[12] VOS W M,TILG H,VHUL M,et al.Gut microbiome and health:Mechanistic insights[J].Gut,2022,71(5):1020-1032.
[13] CROST E H,COLETTO E,BELL A,et al.Ruminococcus gnavus:Friend or foe for human health[J].FEMS Microbiol Rev,2023,47(2):1-23.
[14] ZHAI L,HUANG C,NING Z,et al.Ruminococcus gnavus plays a pathogenic role in diarrhea-predominant irritable bowel syndrome by increasing serotonin biosynthesis[J].Cell Host Microbe,2023,31(1):33-44.
[15] ZHAI L,XIAO H,LIN C,et al.Gut microbiota-derived tryptamine and phenethylamine impair insulin sensitivity in metabolic syndrome and irritable bowel syndrome[J].Nat Commun,2023,14(1):4986-5000.
[16] YOUN H S,KIM J H,LEE J S,et al.Lactobacillus plantarum reduces low-grade inflammation and glucose levels in a mouse model of chronic stress and diabetes[J].Infect Immun,2021,89(8):15-20.
[17] CHEN S,ZHANG Y.Mechanism and application of lactobacillus in type 2 diabetes-associated periodontitis[J].Front Public Health,2023,11(11):1248-1259.
[18] WU J,YANG K,FAN H,et al.Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus[J].Front Endocrinol(Lausanne),2023,14(11):424-436.
[19] PORTINCASA P,BONFRATE L,VACCA M,et al.Gut microbiota and short chain fatty acids:Implications in glucose homeostasis[J].Int J Mol Sci,2022,23(3):1105-1128.
[20] WU Z,TIAN E,CHEN Y,et al.Gut microbiota and its roles in the pathogenesis and therapy of endocrine system diseases[J].Microbiol Res,2023,268(12):72-91.
[21] TOMAS A,JONES B,LEECH C.New insights into Beta-cell GLP-1 receptor and camp signaling[J].J Mol Biol,2020,432(5):1347-1366.
[22] ARORA T,TREMAROLI V.Therapeutic potential of butyrate for treatment of type 2 diabetes[J].Front Endocrinol(Lausanne),2021,12(10):3389-3399.
[23] CUI J,RAMESH G,WU M,et al.Butyrate-producing bacteria and insulin homeostasis:The microbiome and insulin longitudinal evaluation study(MILES)[J].Diabetes,2022,71(11):2438-2446.
[24] DAISLEY B A,KOENIG D,ENGELBRECHT K,et al.Emerging connections between gut microbiome bioenergetics and chronic metabolic diseases[J].Cell Rep,2021,37(10):1016-1035.
[25] PENG K,DONG W,LUO T,et al.Butyrate and obesity:Current research status and future prospect[J].Front Endocrinol(Lausanne),2023,14(10):988-1002.
[26] 范晨雨.促肠上皮细胞吸收短链脂肪酸乳酸菌的筛选及其作用机制[D].扬州:扬州大学,2020.

相似文献/References:

[1]李向辉,卢文杰.葛黄降糖汤治疗2型糖尿病合并颈动脉硬化临床研究*[J].陕西中医,2019,(5):580.
　LI Xianghui,LU Wenjie..Effect of Gehuang Jiangtang decoction on mellitus complicated with carotid arteriosclerosis in type 2 diabetes patients[J].,2019,(6):580.
[2]杨斯皓,马方霞,詹 云.一贯煎合六味地黄汤配合西药治疗2型糖尿病合并非酒精性脂肪肝临床疗效及对患者生活质量的评价*[J].陕西中医,2019,(8):1006.
　YANG Sihao,MA Fangxia,ZHAN Yun..Clinical efficacy and quality of life evaluation of Yiguanjian plus Liuwei Dihuang decoction with western medicine in the treatment of type 2 diabetes with nonalcoholic fatty liver disease[J].,2019,(6):1006.
[3]孙晓红,陈学彬△.芪精丹兰汤对伴有左心室舒张功能不全的2型糖尿病合并代谢综合征患者糖脂代谢、心率变异性的影响*[J].陕西中医,2019,(10):1336.
　SUN Xiaohong,CHEN Xuebin..Effect of Qijing Danlan decoction on glucose and lipid metabolism and heart rate variability in patients with type 2 diabetes mellitus complicated with MS with left ventricular diastolic dysfunction[J].,2019,(6):1336.
[4]訾 璐,胡小军△,王 玉,等.针刺中脘穴联合自拟茶方对2型糖尿病患者血糖水平的影响*[J].陕西中医,2019,(10):1460.
　ZI Lu,HU Xiaojun,WANG Yu,et al.Effect of zhong wan acupuncture combined with selfdesigned tea prescription on blood glucose level in patients with type 2 diabetes mellitus[J].,2019,(6):1460.
[5]文启友,周 伶,马若梦,等.化瘀利尿法论治2型糖尿病探析[J].陕西中医,2021,(6):761.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.021]
[6]谢兆桃,周卓宁,郑 鹏,等.从中焦论治2型糖尿病患者餐后血糖波动[J].陕西中医,2021,(6):764.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.022]
[7]胡全穗,伍宗明.运用中药药对配伍优化消渴病中医防治方案临床研究[J].陕西中医,2021,(8):1084.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.024]
　HU Quansui,WU Zongming.Clinical research on optimizing the TCM prevention and treatment of Xiaoke by using compatibility of herb-partners[J].,2021,(6):1084.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.024]
[8]卢 昉,刘晓霞,梁佩玲,等.清热益气降糖方对2型糖尿病患者胰岛α、β细胞功能的影响[J].陕西中医,2021,(10):1400.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.019]
[9]刘厚利,呼兴华,何 莉,等.基于数据挖掘许建秦治疗湿热内蕴型糖尿病用药规律分析[J].陕西中医,2021,(10):1455.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.035]
[10]陈继玲,任珍珍,王劭敏,等.玉泉丸合生脉散联合二甲双胍治疗气阴两虚证2型糖尿病临床研究[J].陕西中医,2021,(11):1553.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.013]
　CHEN Jiling,REN Zhenzhen,WANG Shaomin,et al.Efficacy of Yuquan pills with Shengmai powder and metformin tablets in the treatment of T2DM with deficiency of Qi and Yin[J].,2021,(6):1553.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.013]

备注/Memo

备注/Memo:
基金项目:广东省中医药局科研项目(20241223); 广州市卫生健康科技项目(20232A010005); 广州市三级名中医工作室研究专项课题[广医中医发(2022)189号]
更新日期/Last Update: 2024-06-11